GK01 cell therapy for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an experimental cell therapy called GK01 for people with advanced lung cancer that has progressed after standard treatments. The goal is to see if this therapy can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced lung cancer that has gotten worse after standard treatment or you couldn't tolerate standard treatment.
- You have at least one tumor that can be measured and hasn't been treated with radiation.
- You are generally able to care for yourself (ECOG score 0 or 1).
- Your doctor expects you to live at least 3 more months.
- You have adequate blood and organ function, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational cell therapy (GK01) for people with advanced solid tumors that have grown despite standard treatment or have no standard treatment option. It may help shrink tumors or slow their growth.
This trial tests a new drug called GK01 in patients with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, and may be an option for those who can have a tumor surgically removed.
This trial tests an experimental treatment called GK01, which uses your own immune cells (called tumor-infiltrating lymphocytes) that have been taken from your tumor, multiplied in a lab, and given back to you. It is for people with advanced solid tumors that have not responded to standard treatments, and aims to see if these cells can shrink your cancer.
This trial tests an investigational drug called GK01, given alone or with chemotherapy, after surgery to remove a solid tumor. The goal is to see if it helps prevent the cancer from coming back.
This trial tests an investigational cell therapy called GKL-006Allo for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this therapy can help shrink or slow the growth of tumors.
This Phase 1/2 trial tests a new treatment called LK101 combined with a PD-1 or PD-L1 antibody for advanced lung cancer. It may help shrink tumors and improve control of the disease, especially after prior anti–PD-1/PD-L1 treatment has stopped working.
Hear when a new Advanced Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.